The Efficacy and Safety of Nafamostat Mesylate in the Treatment of COVID-19 : A Meta-Analysis
Nafamostat mesylate, a synthetic serine protease inhibitor, has demonstrated early antiviral activity against SARS-CoV-2 and anticoagulant properties that may be beneficial in COVID-19. We conducted a meta-analysis evaluating the efficacy and safety of nafamostat mesylate for COVID-19 treatment. PubMed, Embase, Cochrane Library, Scopus, Web of Science, medRxiv and bioRxiv were searched up to July 2023 for studies comparing outcomes between nafamostat mesylate treatment and no nafamostat mesylate treatment in COVID-19 patients. Mortality, disease progression and adverse events were analyzed. Six studies involving 16,195 patients were included. Meta-analysis revealed no significant difference in mortality (OR=0.88, 95%CI: 0.20-3.75, P=0.86) or disease progression (OR=2.76, 95%CI: 0.31-24.68, P=0.36) between groups. However, nafamostat mesylate was associated with increased hyperkalemia risk (OR=7.15, 95%CI: 2.66 to 19.24, P<0.0001). Nafamostat mesylate does not improve mortality or morbidity in hospitalized COVID-19 patients compared to no nafamostat mesylate treatment. The significant hyperkalemia risk is a serious concern requiring monitoring and preventative measures. Further research is needed in different COVID-19 populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Japanese journal of infectious diseases - (2024) vom: 31. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, Mian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 13.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.7883/yoken.JJID.2023.315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368329739 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368329739 | ||
| 003 | DE-627 | ||
| 005 | 20240213232902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7883/yoken.JJID.2023.315 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368329739 | ||
| 035 | |a (NLM)38296543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, Mian |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Efficacy and Safety of Nafamostat Mesylate in the Treatment of COVID-19 |b A Meta-Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Nafamostat mesylate, a synthetic serine protease inhibitor, has demonstrated early antiviral activity against SARS-CoV-2 and anticoagulant properties that may be beneficial in COVID-19. We conducted a meta-analysis evaluating the efficacy and safety of nafamostat mesylate for COVID-19 treatment. PubMed, Embase, Cochrane Library, Scopus, Web of Science, medRxiv and bioRxiv were searched up to July 2023 for studies comparing outcomes between nafamostat mesylate treatment and no nafamostat mesylate treatment in COVID-19 patients. Mortality, disease progression and adverse events were analyzed. Six studies involving 16,195 patients were included. Meta-analysis revealed no significant difference in mortality (OR=0.88, 95%CI: 0.20-3.75, P=0.86) or disease progression (OR=2.76, 95%CI: 0.31-24.68, P=0.36) between groups. However, nafamostat mesylate was associated with increased hyperkalemia risk (OR=7.15, 95%CI: 2.66 to 19.24, P<0.0001). Nafamostat mesylate does not improve mortality or morbidity in hospitalized COVID-19 patients compared to no nafamostat mesylate treatment. The significant hyperkalemia risk is a serious concern requiring monitoring and preventative measures. Further research is needed in different COVID-19 populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Nafamostat mesylate | |
| 650 | 4 | |a hyperkalemia | |
| 700 | 1 | |a Li, Toni |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Siyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yushu |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Ao, Guangyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of infectious diseases |d 1999 |g (2024) vom: 31. Jan. |w (DE-627)NLM104387572 |x 1884-2836 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:31 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7883/yoken.JJID.2023.315 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 31 |c 01 | ||